Improving biopharma BD with AI-powered due diligence
In biopharma business development, companies face increasing pressure to identify the next blockbuster drug with limited resources and time constraints.
drug Assets
In biopharma business development, companies face increasing pressure to identify the next blockbuster drug with limited resources and time constraints.